I agree with Naughty Morty on the need for a trading halt.  But...

I agree with Naughty Morty on the need for a trading halt.  

But I believe that in addition, if the results are unambiguously good, there is enough overlap in the primary and secondary measures of both the trial being reported on and the Mesoblast CHF P3 trial, e.g. HF MACE, other hospitalisation measures, echocardiographic assessments, plus walk tests etc that these results may encourage a potential partner to sign, seal and deliver Partner documents for CHF.

No sure what could be achieved in the 12 hour gap between the AHA session and the Webinar, Sunday evening and overnight to Monday morning US time.  We've been told talks or negotiations have been underway for a while now, maybe there are final versions drawn up, waiting.

As I've said before, I'd be happy if the results reflected the 150m arm of the MSB P2 CHF dose ranging trial, no HF MACE for 36 months, good cardiac remodeling etc.